Overview

Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)

Status:
No longer available

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need.

Details

Lead Sponsor:

Biogen